Eidos Therapeutics’ $122 Million Initial Public Offering


Goodwin advised Eidos Therapeutics on the transaction

Eidos Therapeutics (“EIDX”), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR), closed its public offering of 7,187,500 shares of common stock at a price of $17.00 per share, for gross proceeds of approximately $122.2 million, before deducting underwriting discounts and commissions and other offering expenses payable by Eidos.

Goodwin advised with a team including Mitchell S. Bloom, Stuart M. Cable and Joseph C. Theis, Jr. (Picture)

Involved fees earner: Joseph Theis Jr. – Goodwin Procter; Stuart Cable – Goodwin Procter; Mitchell Bloom – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Eidos Therapeutics Inc.;

Author: Ambrogio Visconti